CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDNK1A Transcription

Resistance to temozolomide (TMZ), the first-line chemotherapeutic drug for glioblastoma (GBM) and anaplastic gliomas, is one of the most significant obstacles in clinical treatment. TMZ resistance is regulated by complex genetic and epigenetic networks. Understanding the mechanisms of TMZ resistance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Ye, Xiang, Liu, Xiaochen, Gao, Min, Gong, Li, Tian, Fei, Shen, Yangli, Hu, Huili, Sun, Gongping, Zou, Yongxin, Gong, Yaoqin
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8050354/
https://ncbi.nlm.nih.gov/pubmed/33869025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.638802
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados